METHODS: A systematic search was conducted across the Cochrane Library, PubMed, Web of Science, EMBASE, CNKI, CBM, VIP, and Wanfang database, encompassing literature on slowing progression of myopia with varying atropine concentrations from database inception to January 17, 2024. Data extraction and quality assessment were performed, and a network Meta-analysis was executed using Stata version 14.0 Software. Results were visually represented through graphs.
RESULTS: Fourteen papers comprising 2475 cases were included; five different concentrations of atropine solution were used. The network Meta-analysis, along with the surface under the cumulative ranking curve (SUCRA), showed that 1% atropine (100%)>0.05% atropine (74.9%) >0.025% atropine (51.6%)>0.02% atropine (47.9%)>0.01% atropine (25.6%)>control in refraction change and 1% atropine (98.7%)>0.05% atropine (70.4%)>0.02% atropine (61.4%)>0.025% atropine (42%)>0.01% atropine (27.4%)>control in axial length (AL) change.
CONCLUSIONS: In Chinese children and teenagers, the five various concentrations of atropine can reduce the progression of myopia. Although the network Meta-analysis showed that 1% atropine is the best one for controlling refraction and AL change, there is a high incidence of adverse effects with the use of 1% atropine. Therefore, we suggest that 0.05% atropine is optimal for Chinese children to slow myopia progression.
方法:在Cochrane图书馆进行了系统搜索,PubMed,WebofScience,EMBASE,CNKI,CBM,VIP,和万方数据库,涵盖了从数据库开始到2024年1月17日不同阿托品浓度减缓近视进展的文献。进行了数据提取和质量评估,使用Stata14.0版软件进行网络Meta分析。结果通过图表直观表示。
结果:共14篇论文,共2475例;使用了五种不同浓度的阿托品溶液。网络元分析,连同累积排名曲线(SUCRA)下的曲面,显示1%阿托品(100%)>0.05%阿托品(74.9%)>0.025%阿托品(51.6%)>0.02%阿托品(47.9%)>0.01%阿托品(25.6%)>控制屈光度变化和1%阿托品(98.7%)>0.05%阿托品(70.4%)>0.02%阿托品(61.4%)>0.025%阿托品
结论:在中国儿童和青少年中,5种不同浓度的阿托品可以减少近视的进展。虽然网络Meta分析显示1%阿托品是控制屈光和AL改变的最佳方法,使用1%阿托品的不良反应发生率很高.因此,我们建议0.05%阿托品是中国儿童延缓近视进展的最佳方案.